David S. Joseph

David S. Joseph

President & CEO

  • 40+ yrs of experience commercializing medtech/pharma
  • Co-founder of 4 companies with successful exits (IPO, M&A)
  • Multiple past and present board positions
  • Chairman and CEO of Othera Pharmaceuticals (2003‐2010), a specialty pharmaceutical company focused on treatments for ophthalmic diseases
  • Co‐founder, President, CEO and Chairman of Orthovita (1999‐2008), an orthobiologics company (IPO in 2006; acquired by Stryker (NYSE:SYK) in 2012 for US$350 million)
  • Co‐founder, President, CEO and Chairman of Surgical Laser Technologies (IPO in 1989; acquired by Photo Medix in 1992)
  • Co‐founder, President, CEO and Chairman of SITE Microsurgical Systems (acquired by Johnson & Johnson Corporation (NYSE:JNJ) in 1983)
  • Prior to entrepreneurial career, over 15 years of executive healthcare management experience
  • Past and present board appointments include two successful acquisitions: Animas Corporation, a diabetes insulin pump technology acquired by Johnson & Johnson for approximately US$515 million in 2006; Morphotek, a privately held biotechnology company acquired by Eisai Pharmaceuticals for approximately US$325 million in 2007; and Allevi, a 3D Bioprinting company
  • MBA in Healthcare Administration degree from Xavier University
  • BA in Business Administration from Kings College
David Karshmer

David Karshmer

SVP, Product Development

  • 25+ yrs of experience in medical device design
  • Founded IDEO Healthcare practice
  • Successful serial entrepreneur (Avisa is 6th start-up)
G. Michael Landis

G. Michael Landis

Chief Financial Officer

  • 25+ years finance and accounting experience
  • Strong public company expertise including capital market transactions, investor relations as well as financial reporting and analysis
  • Over ten years in various financial leadership roles at Lannett Company, Inc., a publicly traded generic pharmaceuticals company
  • Senior level finance and controllership positions at two further publicly traded companies
G. Michael Landis

Richard Murray, MD

Chief Medical Officer

  • 25+ years industry experience
  • Executive at Merck & Co. for many years in commercial, medical and scientific areas, most recently as Vice President and Deputy Chief Patient Officer
  • Management experience in all areas of Medical Affairs, including outcomes research, medical information, academic and professional affairs, field-based medical physicians, and investigator-initiated trials globally
  • Fellow at the Advanced Leadership Initiative at Harvard University
  • Previously a practicing physician in pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania
Barbara Bunger

Barbara Bunger, PhD

VP, Clinical Development

  • 30+ years of industry experience, highly successful track record in development of clinical and regulatory strategy, global clinical research trial operations and overall evidence generation planning required to support reimbursement and market adoption
  • Vice President of Clinical Development and Regulatory Services at Clinical Development and Regulatory Services, LTD., a company providing scientific, clinical research and regulatory services to the biopharmaceutical and medical device industry
  • Worldwide Director, Clinical Research and Corporate Clinical Development at Becton Dickinson
  • Led clinical research and regulatory functions at several clinical and regulatory consulting firms as well as at medtech companies, including Medtronic Spine & Biologics, SI-Bone, Philips Healthcare’s emerging business unit and Triangle Research and Regulatory Services
Graham Timmins

Graham Timmins, PhD

Chief Science Advisor

  • Assoc. Professor of Med. Chemistry at UNM
  • Co-inventor of the Company’s patent portfolio
  • Author/co-author of >50 publications; awarded several federal grants

Subscribe to receive our press releases

Stock Info:
CSE:   AVBT $0.00